Genome-wide Association Study
This study has been terminated.
Information provided by (Responsible Party):
Jeeyun Lee, Samsung Medical Center
First received: December 21, 2011
Last updated: May 13, 2014
Last verified: May 2014
To explore biomarkers predictive of clinical response to Taxane/5-FU/platinum based chemotherapy in esophageal squamous cell carcinoma. To identify negative predictive markers to 5-FU/platinum/Taxane. To elucidate signal transduction pathway attributable to 5-FU/platinum/Taxane resistance. To analyze correlation between the quantity of circulating tumor cells and circulating endothelial cell precursors and treatment response to Taxane/5-FU/platinum based chemotherapy.
Esophageal Squamous Cell Carcinoma.
||Observational Model: Cohort
Time Perspective: Prospective
||Genome-wide Association Study to Predict Treatment Response for Chemotherapy in Esophageal Squamous Cell Carcinoma
Primary Outcome Measures:
| Estimated Enrollment:
| Study Start Date:
| Primary Completion Date:
||June 2012 (Final data collection date for primary outcome measure)
Patients treated with Taxane/5-FU/platinum based chemo.
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
Esophageal squamous cell carcinoma Patients treated with Taxane/5-FU/platinum based chemotherapy.
- Histological confirmed esophageal squamous cell carcinoma
- Patients treated with Taxane or 5-FU or platinum based chemotherapy.
- provision of a signed written informed consent.
- patients not signed written informed consent.
- patient unacceptable for study in the judgement of the investigator.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01498757
|Samsung medical Center
|Seoul, Korea, Republic of |
Samsung Medical Center
No publications provided
||Jeeyun Lee, Professor of Medicine, Sungkyunkwan University School of Medicine, Department of Hematology and Oncology, Samsung Medical Center
History of Changes
|Other Study ID Numbers:
|Study First Received:
||December 21, 2011
||May 13, 2014
||Korea: Food and Drug Administration
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on July 29, 2014
Carcinoma, Squamous Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms, Squamous Cell